These are some of the most popular articles on nordiclifescience.org this year.
2020 has been a very challenging year and a large part of our industry news on our site have consisted of Nordic efforts to handle, treat and prevent COVID-19, but we have also seen Nordic life science companies making progress and announcing positive updates.
A population-based study of the early spread of the new coronavirus in Iceland
Scientists at deCODE genetics and Iceland’s Directorate of Health and the National University Hospital has published a population-based study of the early spread of the SARS-Cov-2 virus, causing COVID-19 disease, in Iceland.
Exclusive interview: Mikael Dolsten, Chief Scientific Officer, Pfizer
The days are busy for Sweden’s Mikael Dolsten. As head of Pfizer’s R&D he is at the scientific forefront of the fight against the COVID-19 pandemic. If everything goes well, the company could begin manufacturing its vaccine candidate by the end of the year.
Continue reading the interview
Different COVID-19 strategies in the Nordic countries
Given the similarity of the Nordic societies, it is interesting to note how differently some of them have reacted to the current COVID-19 crisis, writes Johan Strang, Associate Professor at the Centre for Nordic Studies, the University of Helsinki.
AstraZeneca’s vaccine met primary efficacy endpoint
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalizations or severe cases of the disease were reported in participants receiving the vaccine.
Lund-based research organizations form consortium
A consortium of private and public organisations announces a collaboration that aims to assemble and utilize a platform for rapid response to the current SARS-CoV-2 pandemic as well as future threats.
COVID-19: Industry impact so far
NLS has asked industry organizations in all the Nordic countries about the situation and the impact of the COVID-19 pandemic.
Continue reading the interviews
BerGenBio’s Bemcentinib – potential treatment for COVID-19
BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomized Phase II clinical trial initiative.
Danish coronavirus vaccine passes test in mice
A vaccine against COVID-19, developed by researchers from the University of Copenhagen, has been tested in mice and shows promising results.
Swedish researchers have identified nanobodies that may prevent COVID-19 infection
Researchers at Karolinska Institutet have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.
Vaccibody enters agreement with Genentech and accelerates R&D programs
Vaccibody has announced that it has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers.
10X Genomics acquires Swedish Cartana
US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK.
Novo Nordisk to acquire Emisphere Technologies for USD 1.8 billion
Novo Nordisk has entered into a definitive agreement to acquire Emisphere Technologies, a drug delivery company with technologies such as the Eligen SNAC technology, that enable oral formulations of therapeutics.
Alvotech enters biosimilar partnership in China
Alvotech and Alvotech & CCHT Biopharmaceutical, which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China.
Nanoform launches technology for biologics
Nanoform Finland has announced a technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.